GET DAILY SIGNALSVivoSim Labs (VIVS) Falls -26% Over 30 Days as Dilution Concerns Mount
Key Takeaways
- VIVS shares have declined roughly 26% over the past 30 days, falling from about $0.171 to $0.1271 as of the most recent close.
- The pullback reflects dilution concerns, a newly authorized reverse stock split, and a sharp warrant repricing rather than a single earnings miss.
- VivoSim's core technology continues to advance, including a November collaboration with Chemveda Life Sciences to screen AI-designed drug candidates.
- The company's latest quarterly results showed a materially narrower net loss, but revenue remains below $0.1 million and losses are ongoing.
- The stock reached new 52-week lows in early November, underscoring weak sentiment and elevated microcap volatility.
- For additional context, review VivoSim's Price Targets, Earnings, and Forecast pages.
VivoSim Labs (VIVS) Company Background
VIVS is a pharmaceutical and biotechnology services company based in San Diego, California. Formerly known as Organovo Holdings, the firm rebranded in April 2025 and now trades on the Nasdaq Capital Market. It specializes in testing drugs and drug candidates using three-dimensional human tissue models of the liver and intestine through its proprietary NAMkind™ platforms built on New Approach Methodologies.
The company offers liver and intestinal toxicology and predictive screening services to pharmaceutical and biotech partners, aiming to flag safety issues earlier in development. VivoSim benefits from a regulatory shift at the U.S. Food and Drug Administration that favors human-relevant, non-animal testing methods. Investors track VIVS for its exposure to AI-enabled drug discovery and the emerging NAM testing market, while weighing its small revenue base and ongoing operating losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
VIVS Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, VIVS has fallen approximately 26%, declining from a close near $0.171 in mid-October to $0.1271 as of November 13. The move has been broadly downward, with new 52-week lows reached in early November and a further single-session decline of roughly 8% on November 13.
The decline fits into a longer downtrend. Roughly one quarter ago, the stock closed near $0.32, so VIVS has given back about 60% of its value over the past three months. That quarterly slide followed a sharp but short-lived speculative surge in early August, when the stock spiked on heavy volume before reversing. Since then, shares have trended lower as dilution and capital-structure concerns have taken center stage.
Drivers Behind the Recent 30-Day Decline
The 30-day drop was driven primarily by capital-structure and dilution concerns. In early October, VivoSim disclosed results from its September 30 annual meeting, where shareholders authorized the board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-20 at any time before September 30, 2027. Shareholders also approved repricing certain warrants issued in May 2024 from $9.60 to $0.85 per share and authorized the issuance of roughly 4.7 million additional shares tied to a July 2026 private placement.
These steps signal ongoing financial pressure and a potential need to maintain Nasdaq listing compliance, which weighed on sentiment. The stock continued to make new lows in early November despite positive operational news, including a November 3 collaboration with Chemveda Life Sciences to test AI-designed compounds in VivoSim's human tissue models and a November 10 announcement of data presentations at the American College of Toxicology's annual meeting. VivoSim's November 12 quarterly report showed a narrower net loss versus the prior-year period, but the microcap name continued to face selling pressure, underscoring the market's focus on dilution risk over near-term progress.
Factors Behind the Quarterly Performance
VIVS's roughly 60% decline over the past quarter reflects a combination of an unwinding speculative rally and structural financial concerns. The early-August spike in volume and price proved unsustainable, and the stock has steadily retraced as attention returned to fundamentals. VivoSim generated less than $0.1 million in revenue during its most recent quarter and reported a full fiscal-year 2026 net loss of about $13.84 million on revenue of roughly $131,000.
Financing activity has compounded the pressure. A July 2026 private placement, subsequent warrant exercises, an expanded equity incentive plan, and the reverse-split authorization all point to a heavier potential share count. With a market capitalization near $2 million and limited cash runway, the market has repriced the stock to reflect elevated dilution risk and uncertainty around the company's path to sustainable service revenue.
Key Factors to Watch for VIVS Going Forward
Several elements will shape VIVS in the months ahead. First, investors should monitor whether and how the board uses its reverse-split authority, since a split would affect the share price and outstanding share count without changing the company's market capitalization. Second, revenue trajectory matters: management has said it expects service revenue to grow in coming quarters, and initial pilot contracts carried significant discounts, so gross margin improvement will be an important signal.
Third, the Chemveda Life Sciences collaboration is expected to generate initial programs beginning in the fourth quarter of 2026, making commercial conversion a key milestone. Finally, watch cash position and any additional financings, continued Nasdaq listing compliance, and broader regulatory momentum for non-animal testing methods. These factors will likely determine whether VIVS can stabilize its share price and shift investor focus back to its technology. From what I see, tracking these milestones closely will be essential.
Integrating AI Tools Into Microcap Research
In my own work on names like this, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might respond to similar microcap setups. The platform offers a range of bots that scan thousands of tickers and highlight those aligning with specific risk and timeframe preferences. I find it helpful for gaining a data-driven view of potential entry or exit points without replacing core fundamental analysis. It keeps the process efficient while adding another layer of perspective on volatility patterns common in this space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
VIVS in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 13, 2026
VIVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 45 cases where VIVS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VIVS's RSI Oscillator exited the oversold zone, 38 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in 158 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIVS as a result. In 84 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVS entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.808) is normal, around the industry mean (3.498). P/E Ratio (-0.032) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and commercializing functional human tissues
Industry Biotechnology
Advertisement